In relation to COVID-19, IL-37 has been suggested to be a potential treatment based on its anti-inflammatory profile to inhibit IL-1β, IL-6 and TNF, which are the main players of the cytokine storm (84). This evidence concerns the gene IL1B and COVID-19.